Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation 
    		2019 ASCO Annual Meeting
    	
    	
    	
    
        Patricia A. Ganz, MD, of NRG Oncology and Jonsson Comprehensive Cancer Center at UCLA, discusses the NRG/NSABP phase III findings, which showed that partial-breast irradiation was more convenient and resulted in less fatigue but slightly poorer cosmesis at 36 months in patients who did not receive chemotherapy (Abstract 508).
    
    
    
    
       
       
    		
		
		
        
		
		
		
		Åsmund A. Fretland, MD, of Oslo University Hospital, discusses clinical trial findings on survival outcomes after laparoscopic vs open resection for colorectal liver metastases. The study he conducted with his team showed that the laparoscopic procedure did not jeopardize long-term survival (Abstract LBA3516).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Hope S. Rugo, MD, of the University of California, San Francisco, and Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discuss an update of the IMpassion130 interim overall survival analysis of atezolizumab plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (Abstract 1003).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		David J. Kwiatkowski, MD, PhD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, discusses an interim analysis and biomarker data from a multicenter study showing that 19% of patients with NSCLC had a major pathologic response to preoperative treatment with atezolizumab (Abstract 8503).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphoma (Abstract 7508).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Kim N. Chi, MD, of BC Cancer, discusses the first phase III findings from the TITAN study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen-deprivation therapy (Abstract 5006).